Billions of dollars are spent each year on drugs with unproven clinical effectiveness and limited safety records. Sales of ezetimibe totaled over $4 billion per year in 2010 despite little evidence of benefit on meaningful clinical outcomes as a substitute or adjunct to statin therapy.1 Millions of people were early adopters of rofecoxib (Vioxx) and rosiglitazone (Avandia), only to see these drugs withdrawn or restricted due to safety concerns. What can be done to increase rational prescribing?
Steinman MA. Using Patients to Promote Evidence-Based PrescribingComment on “Communicating Uncertainties About Prescription Drugs to the Public”. Arch Intern Med. 2011;171(16):1468-1469. doi:10.1001/archinternmed.2011.369